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ABSTRACT 
Recent trials of antithrombotic therapy in patients with CAD have demonstrated substantial 
reductions in ischemic stroke. Our aim was to examine ischemic stroke risk in patients with CAD 
and to identify those at highest risk. We examined ischemic stroke risk in patients without AF 
undergoing coronary angiography (CAG) between 2004 and 2012. Patients were stratified 
according to presence or absence of CAD and further stratified by extent of CAD (0 VD, 1 VD, 2 
VD, 3 VD, and diffuse VD). Endpoints were composites of ischemic stroke, transient ischemic 
attack (TIA), and systemic embolism, as well as major adverse cardiovascular and cerebrovascular 
events (MACCE) defined as cardiac death, myocardial infarction, plus ischemic 
stroke/TIA/systemic embolism. Adjusted incidence rate ratios (IRR) were estimated. A total of 
68,829 patients were included, 25,032 had 0 VD, 4,736 had diffuse VD, 18,471 had 1 VD, 10,588 
had 2 VD, and 10,002 had 3 VD. Median follow-up was 4.0 years. CAD extent was associated with 
an increased risk of stroke/TIA/systemic embolism (1VD: adjusted IRR 1.02, 95% CI 0.90-1.16; 
diffuse VD:  adjusted IRR 1.22, 95% CI 1.02-1.47; 2 VD: adjusted IRR 1.28, 95% CI 1.12-1.45; 3 
VD: adjusted IRR 1.37, 95% CI: 1.20-1.55) compared to patients with 0 VD.  Presence and extent 
of CAD were also associated with MACCE. In conclusion, CAD is associated with an increased 
risk of stroke/TIA/systemic embolism and MACCE in patients without AF, and patients with 
coronary MVD are at highest risk and may be candidates for treatment strategies aiming at reducing 
ischemic stroke incidence. 
 
Key words: coronary artery disease, coronary angiography, ischemic stroke, transient ischemic 
attack.
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Cerebral ischemia and coronary artery disease (CAD) share a common pathophysiology.
1
 Recent 
randomized cardiovascular outcome trials have used CAD or obstructive multi-vessel disease 
(MVD) as risk factors and inclusion criteria in order to obtain relative, and relevant, high-risk 
populations.
2, 3
 Some of these studies have shown a benefit that primarily was related to a reduction 
in ischemic stroke.
2, 4
 However, the association between extent of CAD and risk of ischemic stroke 
is not well described. Given ageing populations combined with the medical consequences and 
economic burden created by ischemic stroke, further understanding of risk identification and 
possible prevention of ischemic stroke in patients with CAD is of major relevance. The Western 
Denmark Heart Registry contains information on >240,000 coronary angiographies (CAG) 
registered since 1999.
5
 The current study examined the risk of ischemic stroke, transient ischemic 
attack (TIA), and systemic embolism, as well as major adverse cardiovascular and cerebrovascular 
events (MACCE), according to presence and extent of CAD on CAG in patients without atrial 
fibrillation (AF). 
 
METHODS 
The Western Denmark Heart Registry is a regional database that collects information 
from every invasive cardiac procedure including CAG in Western Denmark.
6
 Patients are identified 
through a unique 10-digit number, which is used in every Danish national and regional registry. The 
personal identifier can be used to cross-link patient information with other registries. The Civil 
Registration System registers, among other things, vital status on every Danish resident.
7
 The 
Danish National Patient Registry contains discharge diagnoses from each contact a Danish resident 
has with the universally covering, taxpayer funded Danish health care system, including visits to 
outpatient clinics and hospitalizations.
8
 The Danish National Database of Reimbursed Prescriptions 
provides information on all redeemed prescription medicine since 2004.
9
 Finally, the Danish 
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Register of Causes of Death records underlying and contributing causes of death stated in death 
certificates.
10
 
We included patients who underwent CAG registered in the Western Denmark Heart 
Registry from July 1, 2004 to July 1, 2012. Patients aged <18 years, patients with previous 
diagnoses of ischemic stroke/TIA or AF in the Danish National Patient Registry, or who had had 
redeemed ≥1 prescription of oral anti-coagulant treatment including new oral anti-coagulants6 
months before  CAG. With follow-up starting 30 days after CAG, patients redeeming prescriptions 
of oral anti-coagulant agents within 30 days after CAG were excluded.
8, 9
 Patients who died or 
emigrated ≤30 days after CAG were also excluded. We stratified patients according to presence or 
absence of CAD. In subgroup analyses, we further stratified patients according to extent of CAD (0-
vessel disease (VD), 1 VD, 2 VD, 3 VD, and diffuse VD). Diffuse VD was defined as non-
obstructive CAD (1-49% lumen narrowing) in ≥1 coronary vessel. 
Congestive heart failure was defined as an ejection fraction ≤40% registered in the 
Western Denmark Heart Registry, or diagnoses of congestive heart failure or left ventricular 
dysfunction before or 1 month after CAG obtained from the Danish National Patient Registry. 
Hypertension was defined as receiving treatment for hypertension at the time of CAG in the 
Western Denmark Heart Registry or diagnoses of hypertension registered in the Danish National 
Patient Registry either before or 1 month after CAG. Diabetes was defined as 1) in treatment with 
insulin ± oral glucose lowering treatment, oral glucose lowering treatment, or dietary treatment for 
diabetes mellitus in the Western Denmark Heart Registry, 2) having diabetes diagnoses  before or 1 
month after CAG in the Danish National Patient Registry, or 3) having redeemed ≥1 prescription of 
diabetes medication 6 months before or 1 months after CAG from the Danish National Database of 
Reimbursed Prescriptions. Previous history of peripheral vascular disease was a composite of 
peripheral arterial disease (PAD) and aortic plaque either before or 1 month after CAG from the 
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Danish National Patient Registry. Previous diagnosis of renal disease defined by the Charlson 
Comorbidity Index before or 1 month after CAG from the Danish National Patient Registry.
11
 
Smoking status was defined as either active smoker or never/former smoker at the time of CAG 
examination as listed in the Western Denmark Heart Registry. 
Treatment with either statin or anti-platelet agents (aspirin and/or adenosine 
diphosphate receptor (ADP) inhibitors) was defined as redeeming ≥1 prescription 6 months before 
and 1 month after CAG obtained through the Danish National Database of Reimbursed 
Prescriptions. 
 Endpoints included a composite of primary and secondary diagnoses of ischemic stroke, 
TIA, or systemic embolism during hospitalization obtained from the Danish National Patient 
Registry. We also examined MACCE, which was a composite of cardiac death from the Danish 
Register of Causes of Death, primary or secondary diagnosis of myocardial infarction (MI) during 
and acute hospitalization from the National Patient Registry, and ischemic stroke/TIA/systemic 
embolism. Follow-up started 1 month after CAG for multiple reasons: 1) to avoid the risk of double 
registration of the same CAG related MI event, when patients were transferred from PCI center to a 
regional hospital, 2) to be able to detect changes in patient medication and registration of 
comorbidity as a results of CAG, 3) to avoid registration of CAG related ischemic stroke incidence. 
Follow-up continued until endpoint event, death, emigration or end of follow-up (December 31, 
2012). We only had access to patients’ death records until December 31, 2011, why MACCE was 
estimated in patients examined from July 1, 2004 – July 1, 2011 with end of follow-up on 
December 31, 2011.  We counted the number of endpoint events during follow-up. Cumulative 
incidence proportion curves of ischemic stroke/TIA/systemic embolism were constructed. We 
estimated event rates per 100 person-years for each endpoint. We also calculated unadjusted and 
adjusted incidence rate ratios (IRRs) using the event as outcome and the natural log of person-years 
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as the offset in a Poisson regression.
12
 Patients with 0 VD were used as reference. We adjusted 
IRRs for sex, age category (<65, 65-74, and ≥75 years), hypertension, diabetes, previous MI, 
congestive heart failure, renal disease, PAD/aortic plaque, smoking, statin treatment, and anti-
platelet treatment. In sensitivity analysis, we censored follow-up if the patient was diagnosed with 
AF prior to diagnosis of ischemic stroke, TIA, or systemic embolism. Stata/IC software version 
13.1 (StataCorp, College Station, Texas, USA) was used for statistical analyses. The study 
complied with the Declaration of Helsinki and was approved by the Danish Data Protection Agency 
(record number 2015-57-0002, identification number AU420). 
 
RESULTS 
 In total, 68,829 patients were included. Of these, 25,032 (36%) had no CAD and 
43,797 (64%) had CAD. Of the latter, 18,471 (27%) had 1 VD, 10,588 (15%) had 2 VD, 10,002 
(15%) had 3 VD, and finally 4,736 (7%) had diffuse VD (Figure 1). Median follow-up was 4.0 
years (IQR 2.1-6.0). 
Patients with CAD were older and more often men and had greater burden of 
comorbidity, such as hypertension, diabetes mellitus, congestive heart failure, and PAD/aortic 
plaque (Table 1). Anti-platelet and statin treatment was also more prevalent among patients with 
CAD. During follow-up, 7.8% of patients with CAD and 6.8% of patients without CAD were 
diagnosed with AF. 
The rate of ischemic stroke/TIA/systemic embolism was increased in patients with 
CAD compared to patients without. The cumulative incidence of ischemic stroke/TIA/systemic 
embolism is presented in Figure 2. In the adjusted analysis, CAD remained associated with an 
increased risk of ischemic stroke/TIA/systemic embolism (Table 2). Furthermore, CAD extent was 
associated with an incremental risk of ischemic stroke/TIA/systemic embolism. Patients with 
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obstructive MVD had an increased risk compared to patients with 0 VD. Diffuse VD was also 
associated with an increased. Similar results were seen when restricting analyses to only ischemic 
stroke and TIA. When censoring follow-up at time of AF diagnosis, the results did not change 
compared to the main analysis (data not shown). Presence and extent of CAD was also associated 
with an increased risk of MACCE. 
 
DISCUSSION 
The primary finding of this study was that presence and extent of CAD was associated 
with an increased risk of ischemic stroke/TIA/systemic embolism in patients without AF. This was 
primarily driven by an increased risk among patients with obstructive MVD but was also found in 
patients with diffuse VD. Obstructive CAD in a single vessel was not associated with any increased 
risk compared to patients with 0 VD. Furthermore, our study confirmed an association between the 
extent of CAD and an incremental risk of MACCE, thereby validating the use of MVD as an 
indicator of a high-risk population.  
 Data examining the association between CAD and ischemic stroke in patients without 
AF are scarce. Stroke risk in relation to CAG has often focused on catheterization-related stroke, 
which is a rare complication to CAG.
13-15
 However, in a case-control study of patients (n=1,183) 
without AF after diagnostic CAG
16
 patients suffering subsequent hemorrhagic or ischemic stroke 
after CAG were more likely to have obstructive MVD (defined as ≥70 coronary stenosis in >1 
coronary vessel) than patients who did not experience stroke, which corresponds with our results. 
Ischemic stroke has been associated with CAD and MI.
17
 Several studies have 
examined incident ischemic stroke and prevalence of CAD, and found that 52% of patients with 
ischemic stroke had asymptomatic obstructive CAD.
18
 Patients with ischemic stroke had a 3% risk 
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of MI within 1 year after the stroke incident.
18
 Cross-sectional coronary computed tomography 
angiography (CTA) studies have also established ischemic stroke as a “CAD equivalent” as 
prognosticator of MI and found that CAD was more prevalent in patients with ischemic stroke.
19, 20
 
Greater plaque burden detected by coronary CTA was much more prevalent among patients with 
ischemic stroke, which again aligns with our findings.
20
 
Guidelines recommend long term aspirin, ACE inhibition, and statins, as well as blood 
pressure lowering where appropriate for patients with obstructive CAD,
21
 as well as for those with 
non-cardioembolic ischemic stroke or TIA.
22
 The Cardiovascular Outcomes for People Using 
Anticoagulation Strategies (COMPASS) trial was a large, double-blinded, randomized study 
examining the effect of anti-platelet and anti-coagulant therapy in patients with stable CAD and 
PAD.
2
 27,395 patients were assigned to rivaroxaban 5-mg BID monotherapy, aspirin monotherapy, 
or combined rivaroxaban 2.5-mg BID and aspirin. Even though the COMPASS trial was not 
specifically designed to prevent stroke, the combination of rivaroxaban 2.5-mg BID and aspirin 
treatment substantially reduced risk of both ischemic stroke (HR 0.51, 95% CI 0.38–0.68) and 
MACCE (HR 0.76, 95% CI 0.66-0.86) compared to patients in aspirin monotherapy. Rivaroxaban 
5-mg BID alone, i.e. without aspirin, did not produce a net benefit but nevertheless reduced 
ischemic stroke risk (HR 0.69, 95% CI 0.53–0.90) compared to aspirin. The PEGASUS (Prevention 
of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo 
on a Background of Aspirin–Thrombolysis In Myocardial Infarction 54) trial was a 3-arm 
randomized clinical trial where patients with previous MI within 1-3 years were assigned to; 60-mg 
ticagrelor twice daily, 90-mg ticagrelor twice daily, or placebo, with simultaneous aspirin treatment. 
The 60-mg dose numerically reduced the risk of stroke (1-year HR 0.73, 95% CI: 0.73-1.13) and 
reduced MACCE significantly (1-year HR 0.82, 95% CI 0.67-0.99) compared to placebo.
23
 In both 
the COMPASS trial and PEGASUS trial obstructive MVD was part of the inclusion criteria to 
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identify high-risk patients who would potentially benefit from more intensive antithrombotic 
treatment. Our real-world data confirm that MVD is associated with an increased risk of ischemic 
stroke/TIA/systemic embolism. These patients may benefit from adjuvant therapy on top of aspirin 
with either rivaroxaban or ticagrelor, which both have been shown to reduce cardiovascular and 
cerebrovascular events.
2, 23
 However, these treatment regiments have, so far, not been included in 
international guidelines and further investigation is required. Furthermore, there is a delicate 
balance between ischemic risk reduction and increased bleeding risk to consider when initiating 
anti-coagulant or escalating anti-platelet therapy. Aspirin combined with rivaroxaban in COMPASS 
(HR 1.70, 95% CI 1.40–2.05) or ticagrelor in PEGASUS (HR 3.22, 95% CI 1.86-5.57) increased 
major bleeding risk compared to aspirin monotherapy, a risk that needs to be taken into account.
2
 
Thus, it is imperative to properly identify CAD patients with a high risk of ischemic stroke, which 
offsets any potential bleeding risk, before recommending newer treatment strategies. 
Endpoint events were identified based on hospital discharge diagnoses from national 
databases instead of individual review of patient records or imaging. However, the stroke diagnoses 
in the Danish National Patient Registry has been found to have a high positive predictive value 
(93%).
24
 The medical doctor who issues the death certificate is responsible for classification of 
cause of death.
10
 Thus, coding of causes of death relies on the individual physician, without any 
central validation. This may affect the validity of information retrieved from the Danish Register of 
Causes of Death. Information regarding the primary exposure (presence and extent of CAD) relied 
on the visual assessment of the CAG by experienced cardiologists but might depend on the acting 
physician. We cannot account for any potential misclassification concerning CAD status at a patient 
level. However, in this large real-world cohort of >68,000 patients undergoing CAG, we found 
incremental ischemic stroke risk with increasing CAD extent and any misclassification would draw 
results towards no difference between groups.  
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CAD is associated with an increased risk of ischemic stroke/TIA/systemic embolism 
and MACCE in patients without AF, driven by an increased risk among patients with MVD. These 
patients may be candidates for treatment strategies aiming at reducing ischemic stroke incidence. 
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Figure 1. Patient selection. 
AF = atrial fibrillation 
CAD = coronary artery disease 
CAG = coronary angiography 
OAC = oral anti-coagulant 
VD = vessel disease 
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Figure 2. Cumulative incidence of ischemic stroke, TIA, and systemic embolism according to extent 
of coronary artery disease with throughout follow-up. 
TIA = transient ischemic attack 
VD = vessel disease 
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Table 1. Characteristics of patients without atrial fibrillation according to presence of coronary 
artery disease. 
 Patients without 
coronary artery disease 
(n=25,032) 
Patients with coronary 
artery disease 
(n=43,797) 
Follow-up in years (inter-quartile range) 4.0 (2.2-6.0) 3.9 (2.0-5.9) 
Median age in years (inter-quartile range) 59.2 (51-68) 65.4 (58-74) 
Male 11,797 (47.1) 31,167 (71.2) 
Active smoker 5,895 (26.3) 14,202 (35.6) 
Hypertension 12,460 (49.8) 25,262 (57.7) 
Diabetes mellitus 2,818 (11.3) 7,409 (16.9) 
Congestive heart failure 2,807 (11.2) 6,511 (14.9) 
Renal disease 640 (2.6) 1,208 (2.8) 
Peripheral artery disease/aortic plaque 951 (3.8) 3,627 (8.3) 
Myocardial infarction 2,480 (9.9) 21,561 (49.2) 
Aspirin treatment 13,669 (54.6) 36,584 (83.5) 
Adenosine diphosphate-inhibitor 
treatment 
1,165 (4.7) 17,879 (40.8) 
Statin treatment 12,186 (48.7) 38,220 (87.3) 
Values are number of patients (%) unless otherwise stated. 
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Table 2. Number events, event rates and incidence rate ratios of stroke, TIA, and systemic 
embolism, as well as major adverse cardiovascular and cerebrovascular events. 
 Patients 
(events) 
Events per 100 
person-years (95% 
CI) 
Unadjusted IRR 
(95% CI) 
Adjusted IRR
*
 
(95% CI) 
Stroke/TIA/systemic embolism 
   
No CAD 25,032 (775) 0.77 (0.71-0.82) 1 1 
CAD 43,797 
(1,890) 
1.10 (1.06-1.16) 1.44 (1.33-1.57) 1.20 (1.08-
1.33) 
1 VD 18,471 (636) 0.86 (0.80-0.93) 1.13 (1.01-1.25) 1.05 (0.93-
1.19) 
2 VD 10,588 (508) 1.18 (1.08-1.29) 1.54 (1.38-1.73) 1.28 (1.12-
1.45) 
3 VD 10,002 (585) 1.46 (1.35-1.59) 1.91 (1.72-2.13) 1.37 (1.20-
1.55) 
Diffuse VD 4,736 (161) 1.13 (0.97-1.32) 1.48 (1.25-1.75) 1.22 (1.02-
1.47) 
Stroke/TIA 
No CAD 25,032 (750) 0.74 (0.69-0.80) 1 1 
CAD 43,797 
(1,798) 
1.05 (1.00-1.10) 1.42 (1.30-1.54) 1.15 (1.03-
1.28) 
1 VD 18,471 (607) 0.82 (0.76-0.89) 1.11 (1.00-1.24) 1.02 (0.90-
1.16) 
2 VD 10,588 (476) 1.10 (1.01-1.21) 1.49 (1.33-1.67) 1.20 (1.04-
1.38) 
3 VD 10,002 (562) 1.40 (1.29-1.52) 1.89 (1.70-2.11) 1.32 (1.15-
1.51) 
Diffuse VD 4,736 (153) 1.08 (0.92-1.26)  1.45 (1.22-1.73) 1.19 (0.98-
1.43) 
MACCE (cardiac death, myocardial infarction, and ischemic stroke/TIA) 
No CAD 22,027 
(1,180) 
1.20 (1.14-1.28) 1 1 
CAD 38,307 
(5,334) 
3.33 (3.24-3.42) 2.76 (2.60-2.95) 1.95 (1.80-
2.12) 
1 VD 16,183 
(1,706) 
2.45 (2.34-2.57) 2.03 (1.89-2.19) 1.63 (1.48-
1.78) 
2 VD 9,403 (1,403) 3.48 (3.31-3.67) 2.89 (2.67-3.12) 2.04 (1.85-
2.25) 
3 VD 9,054 (1,921) 5.17 (4.95-5.41) 4.29 (3.99-4.62) 2.63 (2.40-
2.88) 
Diffuse VD 3,667 (304) 2.33 (2.08-2.61) 1.93 (1.70-2.19) 1.59 (1.38-
1.82) 
* Adjusted for sex, age, congestive heart failure, hypertension, diabetes, renal disease, peripheral artery disease/aortic 
plaque, smoking, statin treatment, and anti-platelet treatment. 
CI = confidence interval 
IRR = incidence rate ratio 
MACCE = major adverse cardiovascular and cerebrovascular events 
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TIA = transient ischemic attack 
VD = vessel disease 
 
 
